AAArmaghan Moravej Aleali

Armaghan Moravej Aleali

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Armaghan Moravej Aleali has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 September 2019
      • Vol. 9  (5) , 436-445
    Open Access

    Effects of saffron on homocysteine, and antioxidant and inflammatory biomarkers levels in patients with type 2 diabetes mellitus: a randomized double-blind clinical trial

    by Hajieh Shahbazian, Armaghan Moravej Aleali, Reza Amani, Foroogh Namjooyan, Bahman Cheraghian, Seyed Mahmoud Latifi, Sara Bahrainian, Ataallah Ghadiri

    Objective: Type 2 diabetes mellitus (T2DM) is one of the most common health problems worldwide. Studies have shown that saffron and its derivatives may have therapeutic potentials in T2DM through reducing plasma glucose. The present study aimed to evaluate the effects of saffron extract on serum anti-inflammatory and antioxidant variables in T2DM patients. Materials and Methods: This was a double-blind randomized clinical trial conducted on 64 T2DM patients. Participants received either 15 mg of saffron or placebo capsules (two pills per day) for 3 months. Anthropometric indices, homocysteine, serum anti-inflammatory and antioxidant variables and dietary intake were assessed pre- and post-intervention. Results: After 3 months of treatment, interleukin-6 (IL-6), and tumor necrosis factor (TNF-alpha) increased significantly in both group (p0.05). Homocysteine decteased significantly in control group (p<0.05). Conclusion: Our results showed no improvement in homocystein levels, antioxidant status and inflammatory biomarkers in T2DM patients after treatment with saffron.


  • Vitamin D level in non-diabetic adult people with metabolic syndrome

    by Bahman Ghaderian, Zivar Shirinpour, Armaghan Moravej Aleali, Seyed Mahmoud Latifi, Seyed Peyman Payami, Reza Amani, Marzieh Ghasemi, Mitra Zaheri Birgani


    • 1 July 2013
      • Vol. 7  (4) , 268-76

    Albuminuria and its correlates in type 2 diabetic patients.

    by Mehrnoosh Zakkerkish, Hajieh Bibi Shahbazian, Heshmatollah Shahbazian, Seyed Mahmoud Latifi, Armaghan Moravej Aleali

    The aim of this study was to determine the prevalence of albuminuria and its correlates and investigate disease management for patients with type 2 diabetes mellitus in Ahvaz. This was a cross-sectional study on the 350 patients with type 2 diabetes mellitus attending the Diabetes Clinic at Golestan Hospital, from October 2010 to September 2011. Demographic characteristics were recorded and height, weight, and blood pressure were measured. Blood urea nitrogen and serum levels of creatinine, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglyceride, and glycosylated hemoglobin A were measured in fasting blood samples. Spot urine and 24-hour urine collection were tested for albumin and kidney ultrasonography was done. A total of 72 of 350 patients (20.6%) had microalbuminuria and 18 (5.1%) had macroalbuminuria. Elevated serum creatinine was seen in 6.9% and azotemia in 6.0%. In multivariable analysis, blood urea nitrogen level, glycosylated hemoglobin A, and duration of diabetes mellitus were associated with urinary albumin excretion (P = .04). A small proportion of the participants achieved optimal treatment goals for modifiable risk factors. Abnormal urinary albumin excretion is seen in one-quarter of type 2 diabetic patients and a small but important number of them have azotemia. Albuminuria was found to be associated with long-term duration of diabetes mellitus, poor glucose control (revealed by high glycosylated hemoglobin A levels), and high blood urea nitrogen. Poor glycemic control may have a significant role in the progression of diabetic nephropathy in these patients.